NeOnc Technologies has announced the initiation of a Phase 2 trial of NEO100 intranasal perillyl alcohol in patients with tumors of the membranes surrounding the brain and/or spinal cord. A Phase 2 trial of the intranasal formulation in patients with grade 4 gliomas was initiated in May 2016 and recently expanded to include patients with a type of astrocytoma. Two Phase 1 trials of NEO100 are also underway, the company said.
The new trial is titled, “An Open-Label, Phase 2 Study of NEO100-02 in Participants with Residual, Progressive or Recurrent High-grade Meningioma” and is expected to enroll 30 patients. According to the study description, “NEO100 will be self-administered four times daily on a 28-day treatment cycle for up to twelve cycles, until disease progression or death, whichever occurs first.”
NeOnc CEO Thomas Chen commented, “Addressing the unique challenges posed by skull-base meningiomas, this trial is tailored to a population with limited alternative treatment options. The difficulty in accessing these tumors frequently results in significant neurological deficits post-surgery, and traditional radiation therapy often proves ineffective.”
NeOnc Executive Chairman Amir Heshmatpour said, “We believe this initiation of our Phase 2 meningioma clinical trial for NEO100-02, along with our lead Phase 2 clinical trials for NEO100-01 also currently underway, strengthens the value of our proprietary drug development platform.”
Read the NeOnc Technologies press release.
